News

Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!

Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!

VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa. Read more or Stream the ceremony!

First participants receive VPM1002 in a late-stage phase III clinical trial in Germany. Read more!

First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic. Read more!

In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus. Read more!

Vakzine Projekt Management GmbH: First volunteer enrolled in Phase II/III Study of SIIPL Tdap vaccine in Comparison with Boostrix® in Healthy Participants. More!

Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!

The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24^th of January 2020 in Nairobi, Kenya.

The VPM employee Alexandra Hierweger received the Uwe Koch-Gromus-PhD-Promotionspreis 2019 for her PhD thesis with the title 'Influence of influenza A virus infections on the maternal immune system during pregnancy'. The ceremony took place on 6^th of December 2019 at the University Medical Center Hamburg-Eppendorf.